Upvote
Downvote
Business Development
Share Job
- Suggest Revision
- Innovative Dermatology and Podiatry Brands Medimetriks Pharmaceuticals, Inc. Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment
- Medimetriks licensed exclusive U.S. commercialization rights to ozenoxacin from Ferrer, a leading, privately held Spanish pharmaceutical company, in March 2014 and announced the completion of the second successful Phase 3 pivotal trial in July 2015.
- Both Phase 3 pivotal studies demonstrated the superiority of ozenoxacin cream, 1%, applied topically twice daily for 5 days, versus placebo on both the clinical and bacteriological endpoints.
- MONTREAL and FAIRFIELD, N.J., Feb. 17, 2016 – Knight Therapeutics Inc. (TSX: GUD) (Knight) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) announced today that Knight has issued a secured loan of up to US$20 million to support Medimetriks' acquisition of the exclusive U.S. development and commercialization rights for OP15406 from Otsuka Pharmaceutical Co., Ltd., a global healthcare company headquartered in Tokyo, Japan.
- Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetriks
Active Job
Updated 11 days agoSimilar Job
Relevance
Active